William Blair reissued their buy rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research note released on Tuesday morning. William Blair also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($0.69) EPS, Q1 2019 earnings at ($1.00) EPS, Q2 2019 earnings at ($1.04) EPS, Q3 2019 earnings at ($0.41) EPS, Q4 2019 earnings at ($0.73) EPS, FY2019 earnings at ($3.17) EPS, FY2020 earnings at ($3.83) EPS, FY2021 earnings at ($4.85) EPS and FY2022 earnings at ($4.46) EPS.

A number of other research firms have also recently issued reports on ONCE. ValuEngine cut shares of Spark Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 8th. UBS Group cut their price objective on shares of Spark Therapeutics from $80.00 to $53.00 and set a neutral rating on the stock in a research report on Wednesday, August 8th. Raymond James set a $82.00 price objective on shares of Spark Therapeutics and gave the stock a buy rating in a research report on Wednesday, August 8th. Mizuho restated a buy rating and issued a $77.00 target price on shares of Spark Therapeutics in a report on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $103.00 target price on shares of Spark Therapeutics and gave the stock a buy rating in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $68.52.

ONCE traded down $3.24 during trading on Tuesday, reaching $42.76. 666,734 shares of the stock traded hands, compared to its average volume of 567,755. The stock has a market capitalization of $1.71 billion, a P/E ratio of -5.60 and a beta of 2.27. The company has a current ratio of 10.71, a quick ratio of 18.14 and a debt-to-equity ratio of 0.09. Spark Therapeutics has a 12 month low of $39.01 and a 12 month high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.04) by ($0.22). The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $27.44 million. Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. Spark Therapeutics’s revenue for the quarter was up 463.2% compared to the same quarter last year. During the same period last year, the company earned ($1.90) EPS. As a group, research analysts predict that Spark Therapeutics will post -1.44 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Spark Therapeutics in the third quarter valued at about $122,000. Bank of Montreal Can increased its position in shares of Spark Therapeutics by 1,045.4% in the third quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 2,969 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Spark Therapeutics in the second quarter valued at about $203,000. Smith Asset Management Group LP increased its position in shares of Spark Therapeutics by 39.6% in the third quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 1,120 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Spark Therapeutics by 100.0% in the third quarter. SG Americas Securities LLC now owns 4,493 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 2,246 shares during the period.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Further Reading: Hedge Funds Explained

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.